
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new bispecific antibody, Ziihera (zanidatamab), for biliary tract cancer (BTC). The dual human epidermal growth factor receptor 2 (HER2)- …